caveolin-1 peptide

Caveolin-1 peptide refers to a class of investigational synthetic peptides derived from the caveolin-1 scaffolding domain (CSD, amino acids 82–101 of caveolin-1). Caveolin-1 (Cav-1) is a membrane protein essential for tissue homeostasis, but its expression is significantly downregulated in fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). Caveolin-1 peptides act as functional mimetics or replacements for endogenous Cav-1, binding to proteins containing caveolin-binding domains (CBD) to regulate cellular signaling. The lead clinical candidate in this class, LTI-03 (also known as CSP7), is a 7-amino acid peptide formulated as an excipient-free dry powder for inhalation. It exerts a dual mechanism of action: it attenuates pro-fibrotic signaling pathways (such as TGF-β/Smad, PKC, and MAPK) to reduce lung scarring, while simultaneously promoting the survival and regeneration of alveolar epithelial cells by inhibiting p53-mediated apoptosis and senescence. LTI-03 is currently in Phase 2 clinical development for the treatment of IPF.

Other names

Cav-1 peptideCav1 peptideCav 1 peptideCavtratinCSD peptideCSPCSP-7CSP7CSP 7LTI-2355LTI2355LTI 2355caveolin-1 scaffolding domain peptidecaveolin1 scaffolding domain peptidecaveolin 1 scaffolding domain peptidecaveolin-1 scaffolding peptidecaveolin1 scaffolding peptidecaveolin 1 scaffolding peptidecaveolin-1-derived peptidecaveolin1-derived peptidecaveolin 1-derived peptide